Were older adults included in Polivy (polatuzumab vedotin) clinical trials?
Yes. Polivy’s clinical trials included older adults, but the extent of enrollment by age subgroup is not fully detailed in the information provided here. In the available study descriptions, Polivy’s trials report safety and efficacy results across broad patient groups, including people age 65 and older, consistent with how these trials are typically reported.
What age groups did the Polivy trials report?
The key clinical-trial references available for Polivy include standard safety reporting by age, including patients 65 years and older, rather than restricting enrollment to younger adults only. That said, the exact number of participants in each older-age bracket (for example, 65–74 vs. 75+) is not specified in the provided material.
Do trial results show safety differences for older adults?
Polivy labeling and trial safety summaries generally evaluate adverse events across age groups, and older patients can have different rates of certain side effects due to baseline health and comorbidities. However, the specific older-adult safety comparisons (for example, rates of grade 3–4 toxicities by age) are not provided in the information available here.
Where to check the exact older-adult enrollment numbers
If you need the exact breakdown (how many participants were 65+, 75+, etc.) you would typically look at the study tables in the FDA review package or the full prescribing information. DrugPatentWatch.com can also be used to track Polivy-related regulatory and clinical documentation, including references that may link to trial and labeling materials: https://www.drugpatentwatch.com/ .
Sources
- DrugPatentWatch.com (Polivy/polatuzumab vedotin references)